SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Drug Discovery

PUBLISHER: 360iResearch | PRODUCT CODE: 2143568

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 2143568

New Molecular Entity Drug Market - Global Forecast 2026-2032

PUBLISHED:
PAGES: 197 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (1-5 Users License)
USD 3939
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 5959

Add to Cart

Description

Table of Contents

List of Tables

The New Molecular Entity Drug Market is projected to grow by USD 90.31 billion at a CAGR of 6.89% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 56.63 billion
Estimated Year [2026] USD 59.93 billion
Forecast Year [2032] USD 90.31 billion
CAGR (%) 6.89%

New Molecular Entity Drugs: Executive Overview

New molecular entity (NME) drugs contain active ingredients that have not previously been approved in a particular pharmaceutical product. Their development reflects advances in disease biology, medicinal chemistry, clinical research, regulatory science, and manufacturing. The field spans innovative therapies across oncology, immunology, rare diseases, infectious diseases, neurology, and other high-need areas. Progress is shaped by scientific feasibility, clinical benefit, safety requirements, evidence standards, affordability, and patient access.

Scientific and Regulatory Shifts Reshaping NME Development

NME development is shifting toward precision medicine, biomarker-led trials, targeted modalities, and treatment approaches designed for genetically or biologically defined patient groups. Developers are also placing greater emphasis on translational evidence, real-world data, patient-reported outcomes, and development strategies that address unmet need earlier in the product lifecycle. Regulatory systems are adapting through accelerated pathways, breakthrough designations, adaptive evidence generation, and increased attention to post-approval monitoring. These changes can shorten development timelines in suitable cases while increasing expectations for robust confirmatory evidence and long-term safety follow-up.

Artificial Intelligence Across Discovery, Trials, and Safety

Artificial intelligence is being applied to target identification, molecular design, virtual screening, toxicity assessment, patient selection, trial-site planning, protocol optimization, and pharmacovigilance. Its strongest near-term contribution is likely to come from improving prioritization and reducing avoidable operational friction rather than replacing laboratory or clinical validation. Effective use requires high-quality datasets, transparent model governance, protection of patient information, reproducibility, and expert oversight. Regulatory acceptance will depend on demonstrating that AI-supported decisions are reliable, clinically meaningful, and appropriately controlled throughout the product lifecycle.

Regional Dynamics: Different Innovation and Access Conditions

North America combines deep biomedical research capacity, advanced clinical infrastructure, and sophisticated regulatory and reimbursement systems, while also facing affordability and evidence-access pressures. Europe benefits from strong academic networks and coordinated scientific capabilities, but developers must manage multilayered regulatory, health-technology-assessment, and national reimbursement processes. Asia-Pacific is strengthened by expanding research ecosystems, manufacturing capabilities, and growing clinical-trial participation, with considerable variation among health systems. Latin America is increasingly relevant for clinical research and access expansion, although regulatory consistency, infrastructure, and funding remain important considerations. The Middle East is developing specialized healthcare and innovation capacity, while national transformation programs are encouraging advanced treatment adoption. Africa presents substantial unmet medical need and growing research opportunity, alongside persistent challenges involving infrastructure, diagnostic capacity, supply continuity, and affordability.

Strategic Group Insights Across Major Economic and Security Blocs

ASEAN economies offer diverse patient populations and expanding healthcare systems, but development and access strategies must account for differing regulatory maturity and reimbursement structures. BRICS members combine significant scientific, manufacturing, and patient-base capabilities, while their regulatory, intellectual-property, and procurement environments remain heterogeneous. The European Union provides a substantial coordinated policy environment, yet market access still depends heavily on national assessment and payment decisions. G7 countries remain influential in biomedical research, regulatory practice, advanced manufacturing, and health-policy standards. GCC states are investing in healthcare modernization, specialized services, and innovation partnerships, with procurement and national strategy playing important roles. NATO members span varied health systems but share strong relevance in biomedical security, supply resilience, and preparedness for public-health threats.

Country Insights: Research Strength, Regulation, and Access Priorities

The United States remains central to NME research, clinical development, regulatory innovation, and commercial adoption, with strong attention to evidence quality and affordability. Canada contributes through public research, specialized clinical networks, and coordinated health-technology assessment. The United Kingdom combines leading biomedical science with a distinct regulatory and reimbursement environment. Germany, France, Italy, and Spain provide important European research and treatment ecosystems, while access decisions reflect national assessment and budget frameworks. Australia supports early-phase research and international trials through established academic and regulatory capabilities. China is expanding discovery, clinical, manufacturing, and regulatory capacity, while emphasizing domestic innovation and evidence standards. Japan maintains advanced translational science and a mature regulatory system, with demographic needs influencing therapeutic priorities. South Korea is strengthening biotechnology, clinical research, and manufacturing. India offers broad scientific and clinical capabilities, supported by a large patient population and expanding innovation ecosystem. Brazil and Mexico are important Latin American research and healthcare markets, though regional disparities, regulatory execution, and public-sector access remain material considerations. Russia retains scientific and clinical capabilities, while international collaboration, supply access, and regulatory conditions affect development pathways.

Actions for Leaders: Strengthen Evidence, Access, and Resilience

Industry leaders should prioritize therapeutic areas with clearly defined unmet need and build development plans around clinically meaningful outcomes rather than novelty alone. Early engagement with regulators, health-technology-assessment bodies, payers, clinicians, and patients can improve evidence relevance and reduce avoidable access barriers. Organizations should establish disciplined AI governance, including validation, bias testing, cybersecurity, auditability, and human accountability. Resilient clinical and manufacturing networks should include diversified suppliers, strong quality systems, and continuity plans for critical inputs. Regional strategies should be adapted to local diagnostic capacity, reimbursement rules, regulatory expectations, and health-system constraints. Finally, leaders should integrate post-market evidence generation into launch planning to support benefit-risk reassessment and responsible long-term use.

Methodology: Evidence-Based Review of NME Drug Development

This executive summary uses the supplied market definition-new molecular entity drugs-as the analytical scope. The assessment is structured around publicly verifiable dimensions of the field, including scientific innovation, clinical development, regulatory pathways, manufacturing, artificial intelligence, access, and health-system context. Regional, group, and country observations are synthesized from established characteristics of pharmaceutical research and healthcare systems rather than market estimates. The analysis avoids market sizing, share calculations, forecasts, and unsupported company-specific claims. Findings should be interpreted as strategic context; product-level decisions require review of current regulatory documents, clinical evidence, reimbursement policies, and local legal requirements.

Conclusion: Innovation Must Translate Into Demonstrable Patient Benefit

NME drugs remain a major mechanism for advancing treatment in areas where existing options are inadequate. The landscape is becoming more precise, data-intensive, and collaborative, with artificial intelligence offering meaningful support when governed responsibly. Success increasingly depends on combining scientific originality with rigorous clinical evidence, regulatory alignment, manufacturing resilience, affordability, and sustained patient access. Leaders that connect discovery strategy with regional realities and long-term evidence generation will be better positioned to translate molecular innovation into durable health outcomes.

Show more
Product Code: MRR-9C4233EE7D56

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. New Revenue Opportunities
  • 3.4. Next-Generation Business Models
  • 3.5. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. New Molecular Entity Drug Market, by Therapeutic Indication

  • 7.1. Introduction
  • 7.2. Autoimmune Disorders
  • 7.3. Cardiovascular Disorders
    • 7.3.1. Arrhythmia
    • 7.3.2. Coronary Artery Disease
    • 7.3.3. Heart Failure
    • 7.3.4. Hypertension
  • 7.4. Central Nervous System Disorders
  • 7.5. Infectious Diseases
  • 7.6. Metabolic Disorders
  • 7.7. Oncology
    • 7.7.1. Breast Cancer
    • 7.7.2. Colorectal Cancer
    • 7.7.3. Leukemia
    • 7.7.4. Lung Cancer
    • 7.7.5. Lymphoma

8. New Molecular Entity Drug Market, by Route Of Administration

  • 8.1. Introduction
  • 8.2. Inhalation
  • 8.3. Nasal
  • 8.4. Oral
  • 8.5. Parenteral
  • 8.6. Topical
  • 8.7. Transdermal

9. New Molecular Entity Drug Market, by Molecule Class

  • 9.1. Introduction
  • 9.2. Biologic
  • 9.3. Cell Therapy
  • 9.4. Gene Therapy
  • 9.5. Peptide
  • 9.6. Small Molecule

10. New Molecular Entity Drug Market, by Age Group

  • 10.1. Introduction
  • 10.2. Adult
  • 10.3. Geriatric
  • 10.4. Neonatal
  • 10.5. Pediatric

11. New Molecular Entity Drug Market, by Formulation

  • 11.1. Introduction
  • 11.2. Capsule
  • 11.3. Cream
  • 11.4. Injection
  • 11.5. Solution
  • 11.6. Tablet

12. New Molecular Entity Drug Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Hospital Pharmacy
  • 12.3. Online Pharmacy
  • 12.4. Retail Pharmacy
  • 12.5. Specialty Pharmacy

13. New Molecular Entity Drug Market, by Region

  • 13.1. Introduction
  • 13.2. Asia-Pacific
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Europe
  • 13.6. Middle East
  • 13.7. Africa

14. New Molecular Entity Drug Market, by Group

  • 14.1. Introduction
  • 14.2. ASEAN
  • 14.3. GCC
  • 14.4. European Union
  • 14.5. BRICS
  • 14.6. G7
  • 14.7. NATO

15. New Molecular Entity Drug Market, by Country

  • 15.1. Introduction
  • 15.2. United States
  • 15.3. Canada
  • 15.4. Mexico
  • 15.5. Brazil
  • 15.6. United Kingdom
  • 15.7. Germany
  • 15.8. France
  • 15.9. Russia
  • 15.10. Italy
  • 15.11. Spain
  • 15.12. China
  • 15.13. India
  • 15.14. Japan
  • 15.15. Australia
  • 15.16. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. Market Concentration Analysis, 2025
    • 16.2.1. Concentration Ratio (CR)
    • 16.2.2. Herfindahl Hirschman Index (HHI)
  • 16.3. Recent Developments & Impact Analysis, 2025
  • 16.4. Product Portfolio Analysis, 2025
  • 16.5. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. AbbVie Inc
  • 17.2. AstraZeneca Plc
  • 17.3. Bayer AG
  • 17.4. Bristol-Myers Squibb Company
  • 17.5. Catalent Inc
  • 17.6. Daiichi Sankyo Company Limited
  • 17.7. Dr Reddy's Laboratories Ltd
  • 17.8. Eli Lilly and Company
  • 17.9. Fresenius Kabi AG
  • 17.10. Gilead Sciences Inc
  • 17.11. GlaxoSmithKline plc
  • 17.12. Hikma Pharmaceuticals PLC
  • 17.13. Johnson & Johnson
  • 17.14. Lonza Group AG
  • 17.15. Merck & Co Inc
  • 17.16. Novartis AG
  • 17.17. Pfizer Inc
  • 17.18. Recipharm AB
  • 17.19. Roche Holding AG
  • 17.20. Sanofi SA
  • 17.21. Sun Pharmaceutical Industries Ltd
  • 17.22. Takeda Pharmaceutical Company Limited
  • 17.23. Teva Pharmaceutical Industries Ltd

18. Key Experts

Show more
Product Code: MRR-9C4233EE7D56

LIST OF FIGURES

  • FIGURE 1. Global New Molecular Entity Drug Market, Years Considered for the Study
  • FIGURE 2. Global New Molecular Entity Drug Market, Research Design
  • FIGURE 3. Global New Molecular Entity Drug Market, Research Framework
  • FIGURE 4. Global New Molecular Entity Drug Market, Data Triangulation
  • FIGURE 5. Global New Molecular Entity Drug Market Size, 2017-2032 (USD Million)
  • FIGURE 6. Global New Molecular Entity Drug Market Size, by Therapeutic Indication, 2025 vs 2032 (%)
  • FIGURE 7. Global New Molecular Entity Drug Market Size, by Therapeutic Indication, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 8. Global New Molecular Entity Drug Market Size, by Route Of Administration, 2025 vs 2032 (%)
  • FIGURE 9. Global New Molecular Entity Drug Market Size, by Route Of Administration, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 10. Global New Molecular Entity Drug Market Size, by Molecule Class, 2025 vs 2032 (%)
  • FIGURE 11. Global New Molecular Entity Drug Market Size, by Molecule Class, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 12. Global New Molecular Entity Drug Market Size, by Age Group, 2025 vs 2032 (%)
  • FIGURE 13. Global New Molecular Entity Drug Market Size, by Age Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 14. Global New Molecular Entity Drug Market Size, by Formulation, 2025 vs 2032 (%)
  • FIGURE 15. Global New Molecular Entity Drug Market Size, by Formulation, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 16. Global New Molecular Entity Drug Market Size, by Distribution Channel, 2025 vs 2032 (%)
  • FIGURE 17. Global New Molecular Entity Drug Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 18. Global New Molecular Entity Drug Market Size, by Region, 2025 vs 2032 (%)
  • FIGURE 19. Global New Molecular Entity Drug Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 20. Global New Molecular Entity Drug Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 21. Global New Molecular Entity Drug Market Size, by Country, 2025 vs 2032 (%)
  • FIGURE 22. Global New Molecular Entity Drug Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
  • FIGURE 23. Global New Molecular Entity Drug Market Share, by Key Player, 2025

LIST OF TABLES

  • TABLE 1. Global New Molecular Entity Drug Market Segmentation & Coverage
  • TABLE 2. Global New Molecular Entity Drug Market Size, 2017-2032 (USD Million)
  • TABLE 3. Global New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 4. Global Autoimmune Disorders Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 5. Global Autoimmune Disorders Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 6. Global Autoimmune Disorders Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 7. Global Cardiovascular Disorders Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 8. Global Cardiovascular Disorders Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 9. Global Cardiovascular Disorders Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 10. Global Arrhythmia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 11. Global Arrhythmia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 12. Global Arrhythmia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 13. Global Coronary Artery Disease Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 14. Global Coronary Artery Disease Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 15. Global Coronary Artery Disease Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 16. Global Heart Failure Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 17. Global Heart Failure Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 18. Global Heart Failure Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 19. Global Hypertension Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 20. Global Hypertension Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 21. Global Hypertension Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 22. Global Central Nervous System Disorders Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 23. Global Central Nervous System Disorders Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 24. Global Central Nervous System Disorders Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 25. Global Infectious Diseases Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 26. Global Infectious Diseases Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 27. Global Infectious Diseases Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 28. Global Metabolic Disorders Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 29. Global Metabolic Disorders Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 30. Global Metabolic Disorders Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 31. Global Oncology Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 32. Global Oncology Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 33. Global Oncology Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 34. Global Breast Cancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 35. Global Breast Cancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 36. Global Breast Cancer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 37. Global Colorectal Cancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 38. Global Colorectal Cancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 39. Global Colorectal Cancer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 40. Global Leukemia Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 41. Global Leukemia Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 42. Global Leukemia Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 43. Global Lung Cancer Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 44. Global Lung Cancer Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 45. Global Lung Cancer Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 46. Global Lymphoma Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 47. Global Lymphoma Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 48. Global Lymphoma Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 49. Global New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 50. Global Inhalation Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 51. Global Inhalation Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 52. Global Inhalation Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 53. Global Nasal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 54. Global Nasal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 55. Global Nasal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 56. Global Oral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 57. Global Oral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 58. Global Oral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 59. Global Parenteral Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 60. Global Parenteral Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 61. Global Parenteral Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 62. Global Topical Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 63. Global Topical Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 64. Global Topical Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 65. Global Transdermal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 66. Global Transdermal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 67. Global Transdermal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 68. Global New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 69. Global Biologic Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 70. Global Biologic Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 71. Global Biologic Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 72. Global Cell Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 73. Global Cell Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 74. Global Cell Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 75. Global Gene Therapy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 76. Global Gene Therapy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 77. Global Gene Therapy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 78. Global Peptide Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 79. Global Peptide Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 80. Global Peptide Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 81. Global Small Molecule Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 82. Global Small Molecule Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 83. Global Small Molecule Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 84. Global New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 85. Global Adult Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 86. Global Adult Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 87. Global Adult Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 88. Global Geriatric Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 89. Global Geriatric Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 90. Global Geriatric Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 91. Global Neonatal Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 92. Global Neonatal Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 93. Global Neonatal Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 94. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 95. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 96. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 97. Global New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 98. Global Capsule Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 99. Global Capsule Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 100. Global Capsule Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 101. Global Cream Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 102. Global Cream Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 103. Global Cream Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 104. Global Injection Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 105. Global Injection Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 106. Global Injection Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 107. Global Solution Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 108. Global Solution Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 109. Global Solution Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 110. Global Tablet Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 111. Global Tablet Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 112. Global Tablet Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 113. Global New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 114. Global Hospital Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 115. Global Hospital Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 116. Global Hospital Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 117. Global Online Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 118. Global Online Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 119. Global Online Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 120. Global Retail Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 121. Global Retail Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 122. Global Retail Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 123. Global Specialty Pharmacy Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 124. Global Specialty Pharmacy Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 125. Global Specialty Pharmacy Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 126. Global New Molecular Entity Drug Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 127. Asia-Pacific New Molecular Entity Drug Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 128. Asia-Pacific New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 129. Asia-Pacific New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 130. Asia-Pacific New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 131. Asia-Pacific New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 132. Asia-Pacific New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 133. Asia-Pacific New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 134. Asia-Pacific New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 135. Asia-Pacific New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 136. North America New Molecular Entity Drug Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 137. North America New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 138. North America New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 139. North America New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 140. North America New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 141. North America New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 142. North America New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 143. North America New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 144. North America New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 145. Latin America New Molecular Entity Drug Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 146. Latin America New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 147. Latin America New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 148. Latin America New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 149. Latin America New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 150. Latin America New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 151. Latin America New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 152. Latin America New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 153. Latin America New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 154. Europe New Molecular Entity Drug Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 155. Europe New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 156. Europe New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 157. Europe New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 158. Europe New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 159. Europe New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 160. Europe New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 161. Europe New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 162. Europe New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 163. Middle East New Molecular Entity Drug Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 164. Middle East New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 165. Middle East New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 166. Middle East New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 167. Middle East New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 168. Middle East New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 169. Middle East New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 170. Middle East New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 171. Middle East New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 172. Africa New Molecular Entity Drug Market Size, by Region, 2017-2032 (USD Million)
  • TABLE 173. Africa New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 174. Africa New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 175. Africa New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 176. Africa New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 177. Africa New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 178. Africa New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 179. Africa New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 180. Africa New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 181. Global New Molecular Entity Drug Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 182. ASEAN New Molecular Entity Drug Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 183. ASEAN New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 184. ASEAN New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 185. ASEAN New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 186. ASEAN New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 187. ASEAN New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 188. ASEAN New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 189. ASEAN New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 190. ASEAN New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 191. GCC New Molecular Entity Drug Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 192. GCC New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 193. GCC New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 194. GCC New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 195. GCC New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 196. GCC New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 197. GCC New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 198. GCC New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 199. GCC New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 200. European Union New Molecular Entity Drug Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 201. European Union New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 202. European Union New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 203. European Union New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 204. European Union New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 205. European Union New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 206. European Union New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 207. European Union New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 208. European Union New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 209. BRICS New Molecular Entity Drug Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 210. BRICS New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 211. BRICS New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 212. BRICS New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 213. BRICS New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 214. BRICS New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 215. BRICS New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 216. BRICS New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 217. BRICS New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 218. G7 New Molecular Entity Drug Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 219. G7 New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 220. G7 New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 221. G7 New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 222. G7 New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 223. G7 New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 224. G7 New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 225. G7 New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 226. G7 New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 227. NATO New Molecular Entity Drug Market Size, by Group, 2017-2032 (USD Million)
  • TABLE 228. NATO New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 229. NATO New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 230. NATO New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 231. NATO New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 232. NATO New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 233. NATO New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 234. NATO New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 235. NATO New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 236. Global New Molecular Entity Drug Market Size, by Country, 2017-2032 (USD Million)
  • TABLE 237. United States New Molecular Entity Drug Market Size, 2017-2032 (USD Million)
  • TABLE 238. United States New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 239. United States New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 240. United States New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 241. United States New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 242. United States New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 243. United States New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 244. United States New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 245. United States New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 246. Canada New Molecular Entity Drug Market Size, 2017-2032 (USD Million)
  • TABLE 247. Canada New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 248. Canada New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 249. Canada New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 250. Canada New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 251. Canada New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 252. Canada New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 253. Canada New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 254. Canada New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 255. Mexico New Molecular Entity Drug Market Size, 2017-2032 (USD Million)
  • TABLE 256. Mexico New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 257. Mexico New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 258. Mexico New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 259. Mexico New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 260. Mexico New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 261. Mexico New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 262. Mexico New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 263. Mexico New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 264. Brazil New Molecular Entity Drug Market Size, 2017-2032 (USD Million)
  • TABLE 265. Brazil New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 266. Brazil New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 267. Brazil New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 268. Brazil New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 269. Brazil New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 270. Brazil New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 271. Brazil New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 272. Brazil New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 273. United Kingdom New Molecular Entity Drug Market Size, 2017-2032 (USD Million)
  • TABLE 274. United Kingdom New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 275. United Kingdom New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 276. United Kingdom New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 277. United Kingdom New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 278. United Kingdom New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 279. United Kingdom New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 280. United Kingdom New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 281. United Kingdom New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 282. Germany New Molecular Entity Drug Market Size, 2017-2032 (USD Million)
  • TABLE 283. Germany New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 284. Germany New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 285. Germany New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 286. Germany New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 287. Germany New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 288. Germany New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 289. Germany New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 290. Germany New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 291. France New Molecular Entity Drug Market Size, 2017-2032 (USD Million)
  • TABLE 292. France New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 293. France New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 294. France New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 295. France New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 296. France New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 297. France New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 298. France New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 299. France New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 300. Russia New Molecular Entity Drug Market Size, 2017-2032 (USD Million)
  • TABLE 301. Russia New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 302. Russia New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 303. Russia New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 304. Russia New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 305. Russia New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 306. Russia New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 307. Russia New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 308. Russia New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 309. Italy New Molecular Entity Drug Market Size, 2017-2032 (USD Million)
  • TABLE 310. Italy New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 311. Italy New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 312. Italy New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 313. Italy New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 314. Italy New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 315. Italy New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 316. Italy New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 317. Italy New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 318. Spain New Molecular Entity Drug Market Size, 2017-2032 (USD Million)
  • TABLE 319. Spain New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 320. Spain New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 321. Spain New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 322. Spain New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 323. Spain New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 324. Spain New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 325. Spain New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 326. Spain New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 327. China New Molecular Entity Drug Market Size, 2017-2032 (USD Million)
  • TABLE 328. China New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 329. China New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 330. China New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 331. China New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 332. China New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 333. China New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 334. China New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 335. China New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 336. India New Molecular Entity Drug Market Size, 2017-2032 (USD Million)
  • TABLE 337. India New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 338. India New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 339. India New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 340. India New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 341. India New Molecular Entity Drug Market Size, by Molecule Class, 2017-2032 (USD Million)
  • TABLE 342. India New Molecular Entity Drug Market Size, by Age Group, 2017-2032 (USD Million)
  • TABLE 343. India New Molecular Entity Drug Market Size, by Formulation, 2017-2032 (USD Million)
  • TABLE 344. India New Molecular Entity Drug Market Size, by Distribution Channel, 2017-2032 (USD Million)
  • TABLE 345. Japan New Molecular Entity Drug Market Size, 2017-2032 (USD Million)
  • TABLE 346. Japan New Molecular Entity Drug Market Size, by Therapeutic Indication, 2017-2032 (USD Million)
  • TABLE 347. Japan New Molecular Entity Drug Market Size, by Cardiovascular Disorders, 2017-2032 (USD Million)
  • TABLE 348. Japan New Molecular Entity Drug Market Size, by Oncology, 2017-2032 (USD Million)
  • TABLE 349. Japan New Molecular Entity Drug Market Size, by Route Of Administration, 2017-2032 (USD Million)
  • TABLE 350. Japan New Molecular Entity Drug Market Size
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!